- Home
- KULR vs ARCT Comparison
KULR vs ARCT Comparison
Compare KULR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KULR | ARCT |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.0M | 192.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KULR | ARCT |
|---|---|---|
| Price | $3.68 | $7.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $40.00 | $38.44 |
| AVG Volume (30 Days) | ★ 2.8M | 522.5K |
| Earning Date | 11-18-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $16,677,036.00 | ★ $97,601,000.00 |
| Revenue This Year | $64.40 | N/A |
| Revenue Next Year | $105.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.92 | N/A |
| 52 Week Low | $2.15 | $5.85 |
| 52 Week High | $21.12 | $24.17 |
Technical Indicators
Market Signals| Indicator | KULR | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.54 | 52.61 |
| Support Level | $3.57 | $6.95 |
| Resistance Level | $4.42 | $7.89 |
| Average True Range (ATR) | 0.37 | 0.39 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 35.14 | 65.48 |
Price Performance
Historical ComparisonAbout KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.